12/23
05:31 am
halo
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory [Yahoo! Finance]
12/23
03:32 am
halo
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
Low
Report
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent Injunction - What's Changed [Yahoo! Finance]
12/23
12:27 am
halo
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
Low
Report
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
12/22
09:34 am
halo
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
Low
Report
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™' [Yahoo! Finance]
12/19
08:04 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
12/18
07:00 am
halo
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Medium
Report
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
12/15
04:07 am
halo
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
Low
Report
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) [Seeking Alpha]
12/8
04:05 pm
halo
Jim Lang Elected to Halozyme's Board of Directors
Low
Report
Jim Lang Elected to Halozyme's Board of Directors
12/4
02:53 pm
halo
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
Low
Report
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]
12/4
01:42 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]
12/4
01:26 pm
halo
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Low
Report
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
12/4
08:43 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
12/2
03:45 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/28
07:02 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/28
02:23 am
halo
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Medium
Report
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term [Yahoo! Finance]
11/27
09:23 am
halo
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here's Why [Yahoo! Finance]
Medium
Report
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here's Why [Yahoo! Finance]
11/25
09:10 am
halo
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/25
08:30 am
halo
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
11/20
12:37 am
halo
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects [Yahoo! Finance]
Low
Report
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects [Yahoo! Finance]
11/19
07:43 pm
halo
What Recent Analyst Upgrades and Partnerships Mean for Halozyme's Evolving Story and Valuation [Yahoo! Finance]
Low
Report
What Recent Analyst Upgrades and Partnerships Mean for Halozyme's Evolving Story and Valuation [Yahoo! Finance]
11/19
01:46 pm
halo
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis [Seeking Alpha]
Low
Report
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis [Seeking Alpha]
11/18
01:13 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $56.00. They now have a "neutral" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $54.00 to $56.00. They now have a "neutral" rating on the stock.
11/18
08:50 am
halo
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Low
Report
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
11/18
06:02 am
halo
Merus and Halozyme link on subcutaneous petosemtamab [Yahoo! Finance]
Low
Report
Merus and Halozyme link on subcutaneous petosemtamab [Yahoo! Finance]
11/17
07:00 am
halo
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Low
Report
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab